vTv Therapeutics (VTVT) Change in Accured Expenses (2014 - 2026)

vTv Therapeutics has disclosed Change in Accured Expenses across 13 years of filings, most recently posting $171000.0 for Q2 2026.

• In Q2 2026, Change in Accured Expenses fell 83.32% year-over-year to $171000.0; the TTM figure through Jun 2026 stood at $1.8 million (up 212.76% YoY), while the FY2025 annual figure was $1.5 million, up 129.34% from the prior year.
• Change in Accured Expenses came in at $171000.0 for Q2 2026 at vTv Therapeutics, down from $264000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $4.6 million in Q3 2025 to a low of -$3.2 million in Q4 2025.
• Average Change in Accured Expenses over 5 years is -$65388.9, with a median of $217500.0 recorded in 2026.
• Year-over-year, Change in Accured Expenses plunged 2143.41% in 2022 and jumped 911.86% in 2025.
• Over 5 years, Change in Accured Expenses stood at $561000.0 in 2022, then climbed by 17.47% to $659000.0 in 2023, then plunged by 281.94% to -$1.2 million in 2024, then tumbled by 170.73% to -$3.2 million in 2025, then surged by 105.27% to $171000.0 in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $171000.0 in Q2 2026, $264000.0 in Q1 2026, and -$3.2 million in Q4 2025.